Immatics Biotechnologies GmbH - Company Profile
Powered by 
All the data and insights you need on Immatics Biotechnologies GmbH in one report.
$295
- Save hours of research time and resources with
our up-to-date Immatics Biotechnologies GmbH Strategy Report
- Understand Immatics Biotechnologies GmbH position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Immatics Biotechnologies GmbH, (Immatics) is clinical-stage developer of peptide-based immunotherapeutic substances for multiple cancer treatments. The company has a unique proprietary technology - XPRESIDENT discovery platform that enables the identification of enormous number of naturally presented tumor-associated peptides (TUMAPs) directly from primary tumor tissue.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer